These payloads release a brake that can stop damaged cells from dying. Attaching the drug to an antibody aims to concentrate that effect in cancer cells.
BCL-XL is an anti-apoptotic protein. Primary preclinical research tested BCL-XL inhibitor conjugates and showed that drug-linker changes altered cardiovascular, kidney and platelet toxicities in animal studies. The resulting linker-payload was incorporated into the B7-H3-directed mirzotamab clezutoclax, or ABBV-155. The original solid-tumor trial is completed in the registry. This represents an apoptosis-directed payload, not proof that antibody targeting removes all toxicity from BCL-XL inhibition.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/